Melissa Epperly - Feb 1, 2023 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Chief Financial Officer
Signature
By: /s/ Melissa B. Epperly
Stock symbol
ZNTL
Transactions as of
Feb 1, 2023
Transactions value $
$0
Form type
4
Date filed
2/1/2023, 06:07 PM
Previous filing
Oct 3, 2022
Next filing
Feb 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Award $0 +102K +34.22% $0.00 400K Feb 1, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZNTL Stock Option (Right to Buy) Award $0 +148K $0.00 148K Feb 1, 2023 Common Stock 148K $23.65 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
F2 Includes 399 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on March 31, 2022.
F3 The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.